Senti Biosciences Stock Performance
| SNTI Stock | USD 3.68 0.17 4.84% |
The entity has a beta of 0.73, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Senti Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Senti Biosciences is expected to be smaller as well. Senti Biosciences right now has a risk of 6.25%. Please validate Senti Biosciences skewness, and the relationship between the value at risk and day median price , to decide if Senti Biosciences will be following its existing price patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Senti Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Senti Biosciences is not utilizing all of its potentials. The recent stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Begin Period Cash Flow | 39.4 M |
Senti |
Senti Biosciences Relative Risk vs. Return Landscape
If you would invest 400.00 in Senti Biosciences on December 22, 2024 and sell it today you would lose (32.00) from holding Senti Biosciences or give up 8.0% of portfolio value over 90 days. Senti Biosciences is currently generating 0.0527% in daily expected returns and assumes 6.2461% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Senti, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Senti Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Senti Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Senti Biosciences, and traders can use it to determine the average amount a Senti Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0084
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | SNTI | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.25 actual daily | 55 55% of assets are less volatile |
Expected Return
| 0.05 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Senti Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Senti Biosciences by adding Senti Biosciences to a well-diversified portfolio.
Senti Biosciences Fundamentals Growth
Senti Stock prices reflect investors' perceptions of the future prospects and financial health of Senti Biosciences, and Senti Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Senti Stock performance.
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (180.17) % | ||||
| Current Valuation | 41.71 M | ||||
| Shares Outstanding | 4.59 M | ||||
| Price To Book | 1.09 X | ||||
| Price To Sales | 57.44 X | ||||
| Revenue | 338 K | ||||
| EBITDA | (61.04 M) | ||||
| Cash And Equivalents | 140.78 M | ||||
| Cash Per Share | 3.24 X | ||||
| Total Debt | 33.54 M | ||||
| Debt To Equity | 0.20 % | ||||
| Book Value Per Share | 14.64 X | ||||
| Cash Flow From Operations | (41.4 M) | ||||
| Earnings Per Share | (15.59) X | ||||
| Total Asset | 97.84 M | ||||
| Retained Earnings | (297.13 M) | ||||
| Current Asset | 7.4 M | ||||
| Current Liabilities | 1.05 M | ||||
About Senti Biosciences Performance
By evaluating Senti Biosciences' fundamental ratios, stakeholders can gain valuable insights into Senti Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Senti Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Senti Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. The company was incorporated in 2016 and is headquartered in South San Francisco, California. Senti Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people.Things to note about Senti Biosciences performance evaluation
Checking the ongoing alerts about Senti Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Senti Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Senti Biosciences had very high historical volatility over the last 90 days | |
| Senti Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 338 K. Net Loss for the year was (52.79 M) with loss before overhead, payroll, taxes, and interest of (29.78 M). | |
| Senti Biosciences currently holds about 140.78 M in cash with (41.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.24. | |
| Senti Biosciences has a poor financial position based on the latest SEC disclosures | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Senti Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Senti Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Senti Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Senti Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Senti Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Senti Biosciences' stock. These opinions can provide insight into Senti Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Senti Stock analysis
When running Senti Biosciences' price analysis, check to measure Senti Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Senti Biosciences is operating at the current time. Most of Senti Biosciences' value examination focuses on studying past and present price action to predict the probability of Senti Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Senti Biosciences' price. Additionally, you may evaluate how the addition of Senti Biosciences to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |